Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2011-08-03

AUTHORS

Ekambar R. Kandimalla , Sudhir Agrawal

ABSTRACT

Toll-like receptors (TLRs) 7, 8, and 9 belong to a family of endosomal receptors that are known to detect pathogen-associated nucleic acid molecular patterns and induce appropriate immune responses. Viral single-stranded RNA is the ligand for TLR7 and TLR8, and bacterial and viral DNA containing unmethylated CpG motifs is the ligand for TLR9. We have extensively studied the structure–activity relationships of synthetic oligonucleotides towards the goal of creating novel agonists of TLRs 7, 8, and 9 to modulate immune responses mediated through targeted receptors. Agonists of TLRs 7, 8, and 9 are being studied as therapeutic agents for various diseases, including cancers, allergies, asthma, and infectious diseases, and also as adjuvants with vaccines. In addition, under certain pathological conditions, TLR7 and TLR9 are shown to recognize immune complexes containing self-nucleic acids and contribute to the progression of autoimmune diseases, including lupus, arthritis, psoriasis, and multiple sclerosis. Using the insights gained by studying the interactions of oligonucleotides with endosomal TLRs, we have created oligonucleotide-based antagonists that inhibit both TLR7- and TLR9-mediated immune responses for the treatment of autoimmune and inflammatory diseases. Out of the large portfolio of oligonucleotide-based TLR agonists and antagonists designed, four candidates are currently being evaluated in clinical trials for a broad range of disease indications. More... »

PAGES

61-93

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/12_2011_138

DOI

http://dx.doi.org/10.1007/12_2011_138

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024627029


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/09", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Engineering", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0303", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Macromolecular and Materials Chemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0305", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Organic Chemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0912", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Materials Engineering", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Idera Pharmaceuticals, 167 Sidney Street, 02139, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.452508.e", 
          "name": [
            "Idera Pharmaceuticals, 167 Sidney Street, 02139, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kandimalla", 
        "givenName": "Ekambar R.", 
        "id": "sg:person.0772330367.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772330367.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Idera Pharmaceuticals, 167 Sidney Street, 02139, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.452508.e", 
          "name": [
            "Idera Pharmaceuticals, 167 Sidney Street, 02139, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agrawal", 
        "givenName": "Sudhir", 
        "id": "sg:person.01124454740.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124454740.04"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2011-08-03", 
    "datePublishedReg": "2011-08-03", 
    "description": "Toll-like receptors (TLRs) 7, 8, and 9 belong to a family of endosomal receptors that are known to detect pathogen-associated nucleic acid molecular patterns and induce appropriate immune responses. Viral single-stranded RNA is the ligand for TLR7 and TLR8, and bacterial and viral DNA containing unmethylated CpG motifs is the ligand for TLR9. We have extensively studied the structure\u2013activity relationships of synthetic oligonucleotides towards the goal of creating novel agonists of TLRs 7, 8, and 9 to modulate immune responses mediated through targeted receptors. Agonists of TLRs 7, 8, and 9 are being studied as therapeutic agents for various diseases, including cancers, allergies, asthma, and infectious diseases, and also as adjuvants with vaccines. In addition, under certain pathological conditions, TLR7 and TLR9 are shown to recognize immune complexes containing self-nucleic acids and contribute to the progression of autoimmune diseases, including lupus, arthritis, psoriasis, and multiple sclerosis. Using the insights gained by studying the interactions of oligonucleotides with endosomal TLRs, we have created oligonucleotide-based antagonists that inhibit both TLR7- and TLR9-mediated immune responses for the treatment of autoimmune and inflammatory diseases. Out of the large portfolio of oligonucleotide-based TLR agonists and antagonists designed, four candidates are currently being evaluated in clinical trials for a broad range of disease indications.", 
    "editor": [
      {
        "familyName": "Murakami", 
        "givenName": "Akira", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/12_2011_138", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-642-30462-0", 
        "978-3-642-30463-7"
      ], 
      "name": "Nucleic Acid Drugs", 
      "type": "Book"
    }, 
    "keywords": [
      "immune response", 
      "TLR-7", 
      "Toll-like receptor 7", 
      "endosomal Toll-like receptors", 
      "Toll-like receptors", 
      "appropriate immune response", 
      "self-nucleic acids", 
      "certain pathological conditions", 
      "TLR agonists", 
      "multiple sclerosis", 
      "autoimmune diseases", 
      "endosomal TLRs", 
      "receptor 7", 
      "inflammatory diseases", 
      "clinical trials", 
      "immune complexes", 
      "CpG motifs", 
      "infectious diseases", 
      "TLR7", 
      "TLR9", 
      "therapeutic agents", 
      "disease indications", 
      "novel agonists", 
      "disease", 
      "molecular patterns", 
      "agonists", 
      "pathological conditions", 
      "endosomal receptor", 
      "receptors", 
      "antagonist", 
      "viral DNA", 
      "response", 
      "asthma", 
      "arthritis", 
      "psoriasis", 
      "sclerosis", 
      "structure-activity relationships", 
      "lupus", 
      "allergy", 
      "TLR8", 
      "TLR", 
      "adjuvant", 
      "vaccine", 
      "cancer", 
      "progression", 
      "trials", 
      "treatment", 
      "interaction of oligonucleotides", 
      "indications", 
      "agents", 
      "RNA", 
      "modulation", 
      "nucleic", 
      "acid", 
      "broad range", 
      "ligands", 
      "DNA", 
      "family", 
      "candidates", 
      "oligonucleotide", 
      "patterns", 
      "addition", 
      "relationship", 
      "goal", 
      "synthetic oligonucleotides", 
      "insights", 
      "conditions", 
      "interaction", 
      "complexes", 
      "range", 
      "motif", 
      "large portfolio", 
      "portfolio"
    ], 
    "name": "Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides", 
    "pagination": "61-93", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024627029"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/12_2011_138"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/12_2011_138", 
      "https://app.dimensions.ai/details/publication/pub.1024627029"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_217.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/12_2011_138"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/12_2011_138'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/12_2011_138'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/12_2011_138'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/12_2011_138'


 

This table displays all metadata directly associated to this object as RDF triples.

151 TRIPLES      22 PREDICATES      100 URIs      90 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/12_2011_138 schema:about anzsrc-for:03
2 anzsrc-for:0303
3 anzsrc-for:0305
4 anzsrc-for:09
5 anzsrc-for:0912
6 schema:author N2bbb647f45c9461b95112acbcbce9821
7 schema:datePublished 2011-08-03
8 schema:datePublishedReg 2011-08-03
9 schema:description Toll-like receptors (TLRs) 7, 8, and 9 belong to a family of endosomal receptors that are known to detect pathogen-associated nucleic acid molecular patterns and induce appropriate immune responses. Viral single-stranded RNA is the ligand for TLR7 and TLR8, and bacterial and viral DNA containing unmethylated CpG motifs is the ligand for TLR9. We have extensively studied the structure–activity relationships of synthetic oligonucleotides towards the goal of creating novel agonists of TLRs 7, 8, and 9 to modulate immune responses mediated through targeted receptors. Agonists of TLRs 7, 8, and 9 are being studied as therapeutic agents for various diseases, including cancers, allergies, asthma, and infectious diseases, and also as adjuvants with vaccines. In addition, under certain pathological conditions, TLR7 and TLR9 are shown to recognize immune complexes containing self-nucleic acids and contribute to the progression of autoimmune diseases, including lupus, arthritis, psoriasis, and multiple sclerosis. Using the insights gained by studying the interactions of oligonucleotides with endosomal TLRs, we have created oligonucleotide-based antagonists that inhibit both TLR7- and TLR9-mediated immune responses for the treatment of autoimmune and inflammatory diseases. Out of the large portfolio of oligonucleotide-based TLR agonists and antagonists designed, four candidates are currently being evaluated in clinical trials for a broad range of disease indications.
10 schema:editor N782d485ba9e246c7b33cc83e87f9a5b8
11 schema:genre chapter
12 schema:isAccessibleForFree false
13 schema:isPartOf N9a7a9575bc2c46af871e61b67d94b56d
14 schema:keywords CpG motifs
15 DNA
16 RNA
17 TLR
18 TLR agonists
19 TLR-7
20 TLR7
21 TLR8
22 TLR9
23 Toll-like receptor 7
24 Toll-like receptors
25 acid
26 addition
27 adjuvant
28 agents
29 agonists
30 allergy
31 antagonist
32 appropriate immune response
33 arthritis
34 asthma
35 autoimmune diseases
36 broad range
37 cancer
38 candidates
39 certain pathological conditions
40 clinical trials
41 complexes
42 conditions
43 disease
44 disease indications
45 endosomal TLRs
46 endosomal Toll-like receptors
47 endosomal receptor
48 family
49 goal
50 immune complexes
51 immune response
52 indications
53 infectious diseases
54 inflammatory diseases
55 insights
56 interaction
57 interaction of oligonucleotides
58 large portfolio
59 ligands
60 lupus
61 modulation
62 molecular patterns
63 motif
64 multiple sclerosis
65 novel agonists
66 nucleic
67 oligonucleotide
68 pathological conditions
69 patterns
70 portfolio
71 progression
72 psoriasis
73 range
74 receptor 7
75 receptors
76 relationship
77 response
78 sclerosis
79 self-nucleic acids
80 structure-activity relationships
81 synthetic oligonucleotides
82 therapeutic agents
83 treatment
84 trials
85 vaccine
86 viral DNA
87 schema:name Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides
88 schema:pagination 61-93
89 schema:productId N254b8451c13f4631958e238ca4503153
90 N7fccac5f3a15436a931475cbe8b582ae
91 schema:publisher Ne33440b98e7c4cfca9afdb9b827edc56
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024627029
93 https://doi.org/10.1007/12_2011_138
94 schema:sdDatePublished 2022-12-01T06:49
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N2d89b973884f48108f3baeb2a202cb89
97 schema:url https://doi.org/10.1007/12_2011_138
98 sgo:license sg:explorer/license/
99 sgo:sdDataset chapters
100 rdf:type schema:Chapter
101 N254b8451c13f4631958e238ca4503153 schema:name dimensions_id
102 schema:value pub.1024627029
103 rdf:type schema:PropertyValue
104 N2bbb647f45c9461b95112acbcbce9821 rdf:first sg:person.0772330367.88
105 rdf:rest Nb2bf6fe7c2334f6098bcb5804855e736
106 N2d89b973884f48108f3baeb2a202cb89 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 N782d485ba9e246c7b33cc83e87f9a5b8 rdf:first Nf78ece20e63a40a9acf7ffc590ddbd19
109 rdf:rest rdf:nil
110 N7fccac5f3a15436a931475cbe8b582ae schema:name doi
111 schema:value 10.1007/12_2011_138
112 rdf:type schema:PropertyValue
113 N9a7a9575bc2c46af871e61b67d94b56d schema:isbn 978-3-642-30462-0
114 978-3-642-30463-7
115 schema:name Nucleic Acid Drugs
116 rdf:type schema:Book
117 Nb2bf6fe7c2334f6098bcb5804855e736 rdf:first sg:person.01124454740.04
118 rdf:rest rdf:nil
119 Ne33440b98e7c4cfca9afdb9b827edc56 schema:name Springer Nature
120 rdf:type schema:Organisation
121 Nf78ece20e63a40a9acf7ffc590ddbd19 schema:familyName Murakami
122 schema:givenName Akira
123 rdf:type schema:Person
124 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
125 schema:name Chemical Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:0303 schema:inDefinedTermSet anzsrc-for:
128 schema:name Macromolecular and Materials Chemistry
129 rdf:type schema:DefinedTerm
130 anzsrc-for:0305 schema:inDefinedTermSet anzsrc-for:
131 schema:name Organic Chemistry
132 rdf:type schema:DefinedTerm
133 anzsrc-for:09 schema:inDefinedTermSet anzsrc-for:
134 schema:name Engineering
135 rdf:type schema:DefinedTerm
136 anzsrc-for:0912 schema:inDefinedTermSet anzsrc-for:
137 schema:name Materials Engineering
138 rdf:type schema:DefinedTerm
139 sg:person.01124454740.04 schema:affiliation grid-institutes:grid.452508.e
140 schema:familyName Agrawal
141 schema:givenName Sudhir
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124454740.04
143 rdf:type schema:Person
144 sg:person.0772330367.88 schema:affiliation grid-institutes:grid.452508.e
145 schema:familyName Kandimalla
146 schema:givenName Ekambar R.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772330367.88
148 rdf:type schema:Person
149 grid-institutes:grid.452508.e schema:alternateName Idera Pharmaceuticals, 167 Sidney Street, 02139, Cambridge, MA, USA
150 schema:name Idera Pharmaceuticals, 167 Sidney Street, 02139, Cambridge, MA, USA
151 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...